Global Market for Biological Product Contract Development and Production (CDMO) Market 2021-2026: Market Opportunities in the Emergence of the Concept of Joint Development of Biological Assets and Designer Cell Lines

The report “Organization for the Development of Biological Products Contracts and Production (CDMO) Market – Growth, Trends, Impact of COVID-19 and Forecasts (2021-2026)” was added in’s offer.

The global market for biologics CDMO (henceforth called the market under study) is estimated at $ 9.93 billion in 2020, and is expected to reach $ 18.90 billion by 2026, registering a CAGR of 11.2% during 2021-2026 (from now on, until as the forecast period).

The global pharmaceutical industry is growing at an exponential rate and is expected to reach annual sales of $ 1.52 trillion by 2023, driven by global economic growth, population growth and aging, and the launch of new products. Although small molecules continue to occupy a prominent market share, large molecules, such as biologics, biologics, and cell and gene therapies, are expected to record the fastest growth over the forecast period.

Although the amounts of large molecules are usually smaller, the segment is growing at a faster rate. Absolute growth in the large molecule market, including native biologics, biosimilarities, and cell and gene therapies, is projected at $ 133 billion by 2023. The size of the original biologics market is expected to reach $ 371 billion by 2023, according to Health Healthcare results.

Cancer therapies are among the main drivers of much of the growth in the biologic market. Even with a faster growth prognosis, in terms of drug approval, small molecules outperform biological drugs. For example, in 2018, the FDA approved 42 new products with small molecules, while the approval for biological agents was only 17. However, the number of approvals for biological agents has been growing steadily in recent years.

The CMO / CDMO service sector is uniquely positioned to respond to some of the challenges facing drug manufacturers in the midst of the COVID-19 pandemic. This pandemic has affected several aspects of the biopharmaceutical industry, from drug development, clinical trials, supply, manufacturing to supply chain logistics. However, the shortage of drugs due to COVID-19 is limited and is expected to remain so in the short term, due to the stock of pharmaceutical products, APIs globally. Among the problems they face in supply chains, China and India are the most affected, as they are the world’s largest manufacturers of active pharmaceutical ingredients (APIs) and generics.

Chinese production facilities have been significantly reduced. The majority were a number of typical workforces that could not return to work, leading to underutilized efficiency at multiple levels in the industry. Furthermore, the US Food and Drug Administration (FDA) announced short-term shortcomings back in February 2020 due to delays in API production.

Major market players include Boehringer Ingelheim Group, Wuxi Biologics, Samsung Biologics, Lonza Group and Fujifilm Diosynth Biotechnologies USA Inc., among others.

Key topics:


1.1 Market Assumption Study and Definition

1.2 Scope of the study




4.1 Market overview

4.2 Market drivers

4.2.1 Access to new technologies and higher execution speed implemented by CDMO

4.2.2 The need for large capital investments to develop capabilities has led to firms choosing an outsourcing model

4.2.3 Lack of internal capacity among emerging drug development companies

4.3 Market challenges

4.3.1 Transfer of complexity and concerns due to infringement of intellectual property rights and patents

4.3.2 Capacity issues related to large molecule drugs

4.4 Market opportunities

4.4.1 The emergence of the concept of joint development of biological agents and design cell lines

4.5 Key considerations involved in the selection of CDMO biological drug suppliers

4.6 Business model analysis – added value, flexible risk sharing and production on time

4.7 Detailed assessment of the impact of COVID-19 on CDMO biologics (race to develop new vaccine and impact on current capacity)

4.8 Key trends in the biopharmaceutical industry

4.9 Coverage on the current use of biological drugs for different types of disease treatment – oncology, infectious, cardiovascular, etc.


5.1 Type

5.1.1 Mammals

5.1.2 Non-mammals (microbiological)

5.2 Type of product

5.2.1 Biological drugs Monoclonal (diagnostic, therapeutic and protein) Recombinant proteins Antisense and molecular therapy Vaccines Other biological agents

5.2.2 Biosimilars

5.3 Geography


6.1 Company profiles

6.1.1 Boehringer Ingelheim Group

6.1.2 Wuxi Biologics

6.1.3 Samsung Biologics

6.1.4 Lonza Group

6.1.5 Fujifilm Diosynth Biotechnologies USA Inc.

6.1.6 Toyobo Co. Limited

6.1.7 Parexel International Corporation

6.1.8 PRA Health Sciences

6.1.9 Binex Co. Limited

6.1.10 JRS Pharma

6.1.11 Rentschler Biotechnology

6.1.12 AGC Biologics

6.1.13 Sandoz Biopharmaceuticals

6.1.14 Catalent Inc.

6.1.15 AbbVie contract manufacturing




For more information on this report, visit

Check out the original version at

Laura Wood, Senior Press Manager
[email protected]
For EST business hours, call 1-917-300-0470
For a free call to USA / CAN 1-800-526-8630
For GMT opening hours call + 353-1-416-8900